Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL)
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).
For more information, please visit ClinicalTrials.gov
|Patient Population||Investigational Product(s)||Phase||Status|
|Ovarian||Lurbinectedin (PM01183)||III||Open and Accruing|